ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements with these filters
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million (approx. ₹633 Crore) to expand production capacity at its Kirkland facility, aiming to double RUBY-FILL® production.
Jubilant Pharmova Ltd has scheduled a board meeting for October 12, 2026, to consider raising funds via Non-Convertible Debentures and other permissible securities.
The Company issued a specimen letter to shareholders regarding withholding of FY 2025-26 final dividend due to incomplete KYC documents, as mandated by SEBI.
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.